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through June 2009) for 32,338 patients aged40 years prescribed ipratropium (IPR)
(N10,617) or tiotropium (TIO) (N9,126) in comparison to fluticasone propionate/
salmeterol combination (FSC) (N12,595). Patients initiating with IPR (and sepa-
rately, TIO) werematched to patients initiating with FSC based on propensity to be
prescribed IPR (separately, TIO), considering demographics, comorbidities and uti-
lization characteristics assessed during 6 months before first IMT claim. RESULTS:
Percentage of each group propensitymatched to FSCwas 80.2%, IPR and 89.1%, TIO.
ORs (95% confidence intervals (CI)) for IPR vs. FSC were: ED - PM 1.86 (1.64-2.10), MR
1.81 (1.57-2.08); Hospitalization – PM 1.47 (1.27-1.70), MR 1.53 (1.35-1.75); ED/Hospi-
talization PM 1.67 (1.50-1.85), MR 1.72 (1.56-1.90). For TIO versus FSC, ORs (95% CI)
were: ED - PM 1.34 (1.14-1.47), MR 1.34 (1.17-1.54); Hospitalization – PM 1.10 (0.94-
1.28), MR 1.19 (1.04-1.37); ED/Hospitalization PM 1.21 (1.07, 1.36), MR 1.28 (1.15, 1.42).
IRRs reflected similar differences between themethods. Compared to FSC patients,
total COPD-related health care costs were higher for IPR (PM&MR, P0.01) and TIO
(PM P0.05, MR P0.01). CONCLUSIONS: The MR and PM methods of adjusting for
baseline differences between treatment populations produce similar results.
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THE CHARIOT STUDY: NOVEL DATA COLLECTION, VIEWING AND DYNAMIC
REPORTING MECHANISM
Arnold RJ1, Groesser K2, Baldwin R3
1Mount Sinai School of Medicine, New York, NY, USA, 2Arnold Consultancy & Technology LLC,
New York, NY, USA, 3epiSolve LLC, Newark, NJ, USA
OBJECTIVES: The significant burden of uncontrolled asthma can be translated into
substantial direct and indirect costs to the US health care system. The objectives of
the Characterization of Allergic Asthma: A Chart Review In Moderate-To-Severe
Disease To Assess Asthma Control, Allergies, Patient Outcomes And Treatment
Study (CHARIOT) study were to assess control of patients withmoderate-to-severe
asthma, examine the natural history of disease, practice patterns and resource
utilization in specialty community practices according to recent National Asthma
Education and Prevention Program guidelines by using a novel online approach to
gathering data and quickly demonstrating results. METHODS: This was a retro-
spective, multicenter, randomized study of 1009 patient charts in 60 US allergy and
pulmonology community practices. Assessment of patient control, the primary
endpoint, was achieved by analyzing data entered via internet-based or paper case
report forms (CRFs) Uncontrolled asthma was defined by occurrence of any of the
events in the recent 12 months of continuous follow-up: systemic corticosteroid
burst; frequent short-acting 2 agonist use; ER visit; asthma exacerbation (hospi-
talization and/or unscheduled visit; limitations on activities; decline in lung func-
tion to80% predicted FEV1 or PEF); daytime dyspnea; doubling of inhaled cortico-
steroid dose; or addition of another controller medication. RESULTS: A total of 114
sites were invited to participate in CHARIOT, with a 63% response rate leading to
site enrollment. Sixty investigator sites participated to completion and, after We-
bEx training, only 1 requested paper CRFs but later elected to use electronic forms.
Data was successfully collected and analyzed within a 3-month period. Of the 365
male and 644 female patients enrolled (mean 43.2 17.1 years), 81.9%were deemed
to be uncontrolled. CONCLUSIONS: Greater than 80% of asthma patients from
specialty practices were uncontrolled with regard to asthma symptoms. The novel
internet technology allowed for efficient data collection frommultiple sites within
a short time frame.
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MODELING THE IMPACT OF MULTIPLE QUIT ATTEMPTS IN SMOKERS USING
DISCRETE EVENT SIMULATION (DES)
Marton J1, Getsios D2, Revankar N2, Willke RJ1, Li Q2, Ishak KJ3, Caro JJ2, Zou KH1,
Xenakis J4
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OBJECTIVES: Smoking cessation models have typically evaluated the impact of a
single quit attempt on long term outcomes in smokers but smoking cessation is
characterized bymultiple quit attempts. A DES was developed to simulate lifetime
smoking patterns and the impact on smoking-related complications and costs.
This study evaluates the effect on predictions when modeling single versus mul-
tiple quit attempts.METHODS: Using data from trials, surveys, and the literature,
the DES simulates individuals’ lifetime smoking behaviors and their impact on
outcomes. The simulation assigns and reassigns the initial outcomes of each quit
attempt, time between quit attempts, relapses, and interventions used in each
attempt (varenicline, bupropion, nicotine replacement, behavioral modification,
unassisted). Comorbidities include myocardial infarction, stroke, COPD, and lung
cancer. Market survey data are used to assign the initial intervention for quit at-
tempts. Only direct costs (2010 $US) are considered. All outcomes are discounted at
3%/year. RESULTS:When analyses are restricted to a single quit attempt, mean life
expectancy in the population is 15.8 years, and QALYs 13.2; the lifetime costs of
treatment and smoking related comorbidities average $55,925. Allowing for multi-
ple quit attempts (average 7.6 attempts/smoker) increases the average time indi-
viduals spend abstinent by 8.8 years. Consequently, predicted life expectancy in-
creases by 1.1 years; QALYs by 0.9. Despite increased smoking intervention costs,
total lifetime costs fall by $3300/smoker. Analyses comparing initial varenicline
treatment to mixed initial treatments and allowing multiple versus single quit
attempts reduces varenicline-related predicted health gains and cost offsets, al-
though both groups have better outcomes with multiple quit attempts. The reduc-
tion is apparent because individuals initially on less effective treatments are able to
quit smoking in subsequent attempts. Nevertheless, varenicline is dominant or
highly cost-effective in both scenarios. CONCLUSIONS: Allowing multiple rather
than single quit attempts in simulating outcomes for smokers provides better in-
formation for decision making.
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MEASUREMENT COMPARABILITY BETWEEN PAPER AND ALTERNATE
VERSIONS: RECOMMENDED ASSESSMENT STEPS USING THE LUNG FUNCTION
QUESTIONNAIRE AS AN EXAMPLE
Dalal AA1, Nelson LM2, Gilligan T2, McLeod LD2, Lewis S2, DeMuro C2
1GlaxoSmithKline, Durham, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: Providing participants with choices in how their data are collected
may lead to greater participation, less missing data, improved data quality, and in
some cases, decreased costs in data collection. To facilitate combining data from
multiple versions, the goals of this study were to provide recommended steps to
assess measurement comparability using a crossover study design and a case-
finding questionnaire, the Lung Function Questionnaire (LFQ), as an example.
METHODS: In the study, the LFQ was administered to participants via paper, Web,
interactive voice response system, and interview. A randomized crossover design
was used to gather data across themultiple administration types. In addition to the
LFQ, participants completed demographic and health questions, and a short ques-
tionnaire regarding their administration preference. Four recommended evalua-
tion steps are described and illustrated using data from the crossover study: 1)
comparisons of the item-level responses and agreement; 2) comparison of mean
scale scores; 3) classification of scores; and 4) questions designed to collect usability
and administration preference. RESULTS: In this example, item-level kappa statis-
tics between the paper and the alternate versions ranged from good to excellent,
intraclass correlation coefficients for mean scores were above 0.70, and the rate of
disagreement ranged from 2% to 14%. In addition, although participants had an
administration preference, they reported few difficulties with the versions they
were assigned. CONCLUSIONS: The steps described provide a guide for evaluating
whether to combine scores across administration versions to simplify analyses and
interpretation under a crossover design. The guide recommends the investigation
of item-level responses, summary scores, and participant usability/preference
when comparing versions. Each of these steps provides unique information to
support a comprehensive evaluation and informed decisions regarding whether to
combine data. Results of this particular study for each of the evaluation steps
supported the use of multiple modes of the LFQ.
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MEASURING COMORBIDITY: AN UPDATED CRITICAL REVIEW OF AVAILABLE
METHODS
Hermansson J1, Carlqvist P1, Kennedy K2, Pietri G2
1Heron AB, Stockholm, Sweden, 2HERON Evidence Development Ltd, Luton, UK
OBJECTIVES: Comorbidities are conditions or diseases besides the one of primary
interest. A comorbidity index condenses all the coexistent conditions to a single
score and comorbidity indexes have been extensively used to adjust analyses for
the impact of comorbidities. De Groot and colleagues published a literature review
in 2003 listing available indexes and reporting their validity.The objective of this
study was to review published methods to measure comorbidity and thereby pro-
vide an update of the publication by de Groot and colleagues.METHODS: A struc-
tured search, using as primary search terms comorbidity, multimorbidity, and co-
existing disease, was undertaken in Embase.com to identify studies published
since 2000 in which an index to measure comorbidity is described. For validity,
correlation coefficients, ratios, explained variance, and the area under the receiver
operating characteristic curve were used. Regression models predicting future
events that were significant or significantly improved after adding comorbidity as
a covariatewas considered to support validity. Parameters used to assess reliability
were among others correlation coefficients. RESULTS: Sixtyfour publications were
studied resulting in twentyfive different indexes, to measure comorbidity were
identified, compared to the thirteen identified by de Groot and colleagues (2003). In
line with previous findings, the Charlson Comorbidity Index (CCI) generated the
greatest number of studies and the most consistent results regarding validity and
reliability. CCI compiles the weighted mortality association of nineteen different
diseases with a number of adaptations for specific circumstances. CONCLUSIONS:
The main finding is that the CCI remains the most used and validated index, and
also a number of new comorbidity indexes have been identified in this study.
Assessment of comorbidity is an area of interest for both health economists and
epidemiologists and it seems to be receiving increased attention.
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MEASURING DRUG THERAPY GUIDELINES ON OUTCOMES: A TUTORIAL
Baser O
STATinMED Research, Ann Arbor, MI, USA
OBJECTIVES: To introduce amethod that combines the propensity score matching
and interrupted time-series models to measure drug therapy guidelines on
outcomes.METHODS: Propensity score matching is used to balance groups before
the trend is analyzed. The “kitchen sink” approach is used for propensity score
matching. Interrupted time-series models are applied over the matched sample.
The time-series model contains two predictor variables: the binary intervention
variable and an interval coding for time. This model controls for the confounding
influence of any underlying trend and ensures that any estimated change in the
mean level of the series after intervention is not simply due to the fact that the
series was already decreasing or increasing. RESULTS: To illustrate the model,
changes in the utilization of two hypothetical drugs were analyzed after issuance
of guidelines. Patients who used these two drugs were different at the baseline in
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terms of observable characteristics such as age, gender, and comorbidities
(p0.001). Samples were balanced with nearest neighbor matching. Then seg-
mented time-series models were applied. There was a significant association be-
tween the onset of intervention and the level of utilization of these drugs.
CONCLUSIONS: To isolate the effects of guidelines, we need to control for three
different factors: 1) baseline differences between the two groups; 2) stepwise dif-
ferences at the intervention point; and 3) trend differences after the intervention.
We showed that propensity scorematching can be used for the first factor, and the
latter two can be controlled with the interrupted time-series model.
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THE BURDEN OF CAREGIVING: ASSESSING THE STATUS OF CURRENT CLINICAL
RESEARCH
Hamer N, Costello S, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: The burden of caregiving is high. In 2009 therewere an estimated 65.7
million caregivers in the U.S. (29% of the adult population) and these numbers are
expected to swell in the coming years with the ageing population. Caregiving im-
pacts on the health, wellbeing and work productivity of the caregiver, therefore
research aimed at assessing and reducing the burden of caregiving is warranted.
The objective of this study was to assess the status of current clinical research into
the burden of caregiving. METHODS: Clinicaltrials.gov was searched for trials
where caregiver burden (CB) was reportedly measured. Information on the care-
recipient condition (CRC), the primary focus of the study, and the type of interven-
tion being considered, was extracted from the included trials. RESULTS: 80 trials
were identified that measured a reported outcome of CB. The most common CRC
was Alzheimer’s disease and related disorders (34 studies); followed by cancer (14),
frail and elderly (8), mental health (7), Parkinson’s disease (7), brain and spinal cord
injury (5) and ‘other’ (5). A range of questionnaire-based instruments were report-
edly used across studies to elucidate the physical, emotional (psychological), social
and financial impacts of caregiving.The role or burden of the caregiver was a key
focus in 55% of the studies; trials involving care of cancer patients had the highest
proportion of caregiver-focused studies (12/14, 86%). Behavioural and drug inter-
ventions were the most frequently investigated intervention type (38% and 25% of
trials, respectively), although no studies investigating a ‘drug’ intervention evalu-
ated the effect on caregivers as a primary outcome. CONCLUSIONS: Current clini-
cal research into the burden of informal caregiving is concentrated in age-related
CRCs. Research interventions aimed at relieving CB are mostly behavioural in na-
ture. The growing number of caregivers means that research into effective meth-
ods of reducing CB will be of ever increasing importance.
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WHAT IS IMPORTANT DURING THE PHARMACOECONOMIC EVALUATION OF
CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)?—A SURVEY
RESEARCH
Zhang F1, Li SC2, Fu S1, Xie J1, Zhang Y1, Kong L1
1Shenyang Pharmaceutical University, ShenYang, Liaoning, China, 2University of Newcastle,
Callaghan, NSW, Australia
OBJECTIVES: The increasing popularity of Complementary and Alternative Medi-
cine (CAM) leading to an increasing interest of CAM assessment through phar-
macoeconomic evaluation. The attempts, however, have been unsatisfactory. This
study attempted to survey expert practitioners in China of TCM (Traditional Chi-
nese Medicine) which is a major part of CAM to elucidate critical issues when
assessing cost-effectiveness of TCM, and to ascertain influencing factors of mea-
suring HR-QOL in TCM. METHODS: A questionnaire (with 20 close and open-end
questions) was distributed to TCM practitioners who had been working in the field
for at least 5 years and had published at least one related paper in the last 5 years.
The questions were divided into two modules with module 1 about the issues of
pharmacoeconomic of TCM, andmodule two about the influencing factors of mea-
suring HR-QOL in TCM. Correlation and Partial Correlate test using age and profes-
sional field as control variable were used to module 1 and 2 respectively, non-
related factors were excluded. Principal Component Analysis (PCA) was performed
for remaining items. RESULTS: Of 429 questionnaires issued, 137 were recovered
from 31 medical and research institutions of 8 provinces and cities in China giving
a recovered rate 31.93%. Module 1 and 2 all passed the KMO and Bartlett’s test of
sphericity test (kmomodule 10.56, kmomodule 20.66). Module 1 extracted 4 common
factors after the Rotation Factor Analysis with cumulative variance of 69.9%, while
Moduel 2 extracted 3 with cumulative variance of 70.6%. CONCLUSIONS: The com-
mon factors fromModule 1 prompted us to pay attention to during the pharmaco-
economic evaluation: patient preference; long-term outcomes; the alternative of
TCM; and the overall economic burden of patients.The common factors fromMod-
ule 2 required us to note during the HR-QOL research: Acceptance level of the
measurement scale by patients and physicians; disease complexity; and whether
HR-QOL scale reflects the characteristics of TCM.
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A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD
STUDIES IN SUB-SAHARA AFRICA
Kangethe AW, Franic D
University of Georgia, Athens, GA, USA
OBJECTIVES: The primary objective is a review, classification and critical appraisal
of contingent valuationmethod (CVM) healthcare studies conducted in Sub-Sahara
Africa based on criteria by O’Brien and Gafni (1996). The secondary objective is to
determine the impact of the Bamako Initiative adopted in the early 1990s on CVM
studies in the same setting. METHODS: CVM African healthcare studies (willing-
ness to pay (WTP) and willingness to accept (WTA)), were identified using a com-
prehensive literature search in EconoLit, Google Scholar, Medline, PubMed and
Web of Science between 1981 to 2010. CVM studies evaluated included WTP and
WTA studies reporting primary data were included for evaluation. Primary assess-
ment of the studies was based on the conceptual framework for evaluation of
contingent valuation of healthcare programs (5 Items)(O’Brien and Gafni 1996).
Secondary assessment was based on the time horizon of publication: pre-, during-
(1990s), or post- BI, and area of intervention. RESULTS: Twenty-four CVM studies
were evaluated: all used WTP and compensating variation. Elicitation techniques
were dominated by bidding game (42%), followed by dichotomous choice (33%), and
then payment card and the open ended formats (12.5%). Majority of studies (83%)
were published after 2000, the remainder were published in the 1990s. Interven-
tions included insurance (25%), medication (38%), and health services (38%).
CONCLUSIONS: Healthcare CVM studies in Sub-Sahara Africa are limited despite
the introduction of Bamako Initiative. The predominance of the bidding game elic-
itation technique in evaluated studies may be a reflection of the actual African
market conditions. There is continuing debate as to which is the most appropriate
CVM for healthcare studies conducted in Africa This debate will continue until
these methods are compared to actual markets. CVM studies may start to engage
the political market as Africa moves towards universal health coverage.
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DEVELOPMENT OF AN INCREMENTAL COST-EFFECTIVENESS RATIO WITH
SOME EQUITY IMPLICATION
Wang JD1, Hung MC2
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OBJECTIVES: The conventional ICER (incremental cost-effectiveness ratio), which
quantifies howmany dollars are spent per QALY (quality-adjusted life year) gained
from a specific health technology, has been criticized as unfair to the aged and/or
physically challenged. METHODS: By taking the position that every life is equally
important and every citizen is entitled to access health care services for the entire
duration of his/her life expectancy, we replace the denominator of the conven-
tional ICER, with the proportion of life, which is the quality-adjusted life expec-
tancy (QALE) gained from the specific health technology divided by the QALE of the
corresponding age- and gender-matched general population. The numerator is
converted to the additional monetary cost spent over a lifetime after adjustment
for annual discount rate. The new indicator quantifies howmany dollars are spent
to save the life of a person with a specific illness, and how much can be saved by
preventing the occurrence of that illness. RESULTS: We have applied the estima-
tion method to compare patients with liver cancer; breast cancer, acquired immu-
nodeficiency syndrome, maintenance hemodialysis and peritoneal dialysis, and
prolongedmechanical ventilation.CONCLUSIONS: Because the proposed indicator
accounts for a fair opportunity for the aged and disabled more than the conven-
tional ICER does, we recommend that this indicator be applied in future delibera-
tions of health care resource allocation.
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DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED
STATES: THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING
Iaconi A, Khalidi N, Olanrewaju O, Balkrishnan R
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Determination of the price of a drug starts in its early developmental
stages and it is driven by various competitive healthmarket forces. The purpose of
the study is to explore associations between pharmaceutical pricing and the value
of drugs. METHODS: Based on FDA indications we have identified three different
drug categories: life saving drugs, drugs that are not life saving but save lives
overtime, and drugs that only treat disease symptoms and affect QOL. We have
investigated our theory of an association between drug intended outcomes and the
price tag placed on a drug by performing a literature review of cost analyses for
drugs selected in each category. The literature review included a combination of
key words such as the name of the drug, cost-effectiveness, cost-utility, and QALY.
We identified articles from the past 10 years published only in the English lan-
guage. For each drug, studies reporting ICER/QALY values were selected. ICER/
QALY data were recorded and the values of the three categories were compared
among each other and with the published acceptable QALY threshold value of
US$64,000.RESULTS: For the life saving drugs group the highest ICER/QALY value is
US$150,843 and lowest is €6,880, for the disease ameliorating drugs group €105,599
and US$544, and for the drugs treating disease symptoms and affecting QOL
£154,831 and $US1,056 respectively. Themajority of drugs in the first categorywere
found to have ICER/ QALY values greater than the $64,000 value, while themajority
of the drugs selected in the second and third categories were found to have ICER/
QALY values smaller than the $64,000 value. CONCLUSIONS: From our study we
have found that drugs that are life saving aremore likely to have ICER/QALY values
greater than the threshold values compared to drugs that are disease ameliorating
and that are designed to improve patients’ QOL.
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LEGAL RESTRICTIONS ON THE USE OF QALYS IN PHARMACOECONOMIC
ANALYSIS IN GERMANY
Gissel C, Goetz G, Repp H
Justus Liebig University Giessen, Giessen, Hessen, Germany
OBJECTIVES: In contrast to theNational Institute for Health and Clinical Excellence
(NICE), the German Institute for Quality and Efficiency in Health Care (IQWiG) does
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